T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2676
VirnetX Holding Corp
VHC
$67.6M
| $247K | ﹤0.01% |
4,747
+1,340
| +39% | +$93K |
|
2677
Voyager Therapeutics
VYGR
$200M
| $246K | ﹤0.01% |
90,900
+1,500
| +2% | +$5.12K |
|
2678
Standex International
SXI
$3.97B
| $245K | ﹤0.01% |
2,214
-204
| -8% | -$22.2K |
|
2679
SunCoke Energy
SXC
$781M
| $243K | ﹤0.01% |
36,813
-1,423
| -4% | -$9.43K |
|
|
TCS
2680
DELISTED
THE CONTAINER STORE GROUP, INC.
TCS
| $243K | ﹤0.01% |
1,621
-253
| -14% | -$42.7K |
|
|
TA
2681
DELISTED
TravelCenters of America LLC
TA
| $243K | ﹤0.01% |
+4,707
| New | +$255K |
|
2682
FRP Holdings
FRPH
$424M
| $241K | ﹤0.01% |
8,348
-152
| -2% | -$4.37K |
|
2683
Precigen
PGEN
$2.34B
| $241K | ﹤0.01% |
64,866
+44,100
| +212% | +$190K |
|
2684
UFP Technologies
UFPT
$2.49B
| $240K | ﹤0.01% |
3,410
-3,637
| -52% | -$241K |
|
|
PRTY
2685
DELISTED
Party City Holdco Inc.
PRTY
| $240K | ﹤0.01% |
43,086
-1,700
| -4% | -$11.3K |
|
2686
CareCloud
CCLD
$105M
| $236K | ﹤0.01% |
37,400
+300
| +0.8% | +$2.13K |
|
2687
AST SpaceMobile
ASTS
$21.5B
| $235K | ﹤0.01% |
+29,600
| New | +$304K |
|
|
NPKI
2688
NPK International
NPKI
$1.18B
| $235K | ﹤0.01% |
79,820
+19,600
| +33% | +$62.9K |
|
2689
Pathward Financial
CASH
$1.79B
| $234K | ﹤0.01% |
3,914
-135
| -3% | -$8.06K |
|
2690
4D Molecular Therapeutics
FDMT
$604M
| $234K | ﹤0.01% |
+10,675
| New | +$262K |
|
2691
FTC Solar
FTCI
$40.1M
| $234K | ﹤0.01% |
+3,094
| New | +$254K |
|
2692
Beam Global
BEEM
$25.8M
| $233K | ﹤0.01% |
+12,522
| New | +$342K |
|
2693
MVB Financial
MVBF
$394M
| $232K | ﹤0.01% |
5,576
-158
| -3% | -$6.67K |
|
2694
Distribution Solutions Group
DSGR
$1.61B
| $231K | ﹤0.01% |
8,438
-200
| -2% | -$5.08K |
|
2695
Melco Resorts & Entertainment
MLCO
$2.13B
| $231K | ﹤0.01% |
22,700
-3,305
| -13% | -$35.2K |
|
2696
TherapeuticsMD
TXMD
$24.1M
| $231K | ﹤0.01% |
12,996
+10,352
| +392% | +$310K |
|
2697
Bionano Genomics
BNGO
$13.4M
| $229K | ﹤0.01% |
128
-43
| -25% | -$115K |
|
2698
Northrim BanCorp
NRIM
$602M
| $229K | ﹤0.01% |
21,052
-400
| -2% | -$4.42K |
|
|
XXII
2699
22nd Century Group
XXII
$1.42M
| – | – |
0
| – | – |
|
|
FMTX
2700
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $227K | ﹤0.01% |
+15,995
| New | +$277K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.